The DAWN antivirals trial: process evaluation of a COVID-19 trial in general practice
et al., BJGP Open, doi:10.3399/bjgpo.2023.0109, DAWN, NCT04730206, Nov 2023
Small early terminated RCT showing better recovery with camostat treatment, without statistical significance.
Study covers TMPRSS2 inhibitors, camostat, and molnupiravir.
|
risk of no recovery, 32.6% lower, RR 0.67, p = 0.70, treatment 4 of 19 (21.1%), control 5 of 16 (31.2%), NNT 9.8, day 30.
|
|
risk of no recovery, 22.8% lower, RR 0.77, p = 0.48, treatment 11 of 19 (57.9%), control 12 of 16 (75.0%), NNT 5.8, day 8.
|
|
recovery time, 25.0% lower, relative time 0.75, treatment 19, control 17.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
Tare et al., 20 Nov 2023, Double Blind Randomized Controlled Trial, placebo-controlled, Belgium, peer-reviewed, median age 55.0, 11 authors, trial NCT04730206 (history) (DAWN).
Contact: ann.vandenbruel@kuleuven.be.
DOI record:
{
"DOI": "10.3399/bjgpo.2023.0109",
"ISSN": [
"2398-3795"
],
"URL": "http://dx.doi.org/10.3399/bjgpo.2023.0109",
"abstract": "<jats:sec><jats:title>Background</jats:title><jats:p>The DAWN Antivirals trial was a multicentric, randomised placebo-controlled trial evaluating antiviral medication for COVID-19 in general practice. The trial was prematurely terminated because of insufficient recruitment.</jats:p></jats:sec><jats:sec><jats:title>Aim</jats:title><jats:p>To explore which factors contributed to the premature termination.</jats:p></jats:sec><jats:sec><jats:title>Design & setting</jats:title><jats:p>General practice in Belgium.</jats:p></jats:sec><jats:sec><jats:title>Method</jats:title><jats:p>Patients were randomized to camostat or placebo (blinded) between June 2021 and July 2022); a third arm evaluating molnupiravir (open label) was opened in March 2022. We analysed available trial data and evaluated trial context, implementation and mechanisms of impact based on semi-structured interviews with trial stakeholders.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>The trial recruited 44 participants; 19 were allocated to camostat (median age 55 years), 8 to molnupiravir (median age 60 years) and 17 to placebo (median age 56 years). There were no serious adverse events in either group. Most difficulties were related to the pandemic context: disruption to routine clinical services; multiple changes to the service model for COVID-19 patients; overwhelmed clinical staff; delays of trial medication; staff shortages in the sponsor and clinical team. In addition, regulatory approval processes were lengthy and led to additional study procedures. It was felt that the trial started too late, when vaccinations had already begun.</jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p>The DAWN Antivirals trial was stopped prematurely. Although many barriers were related to the pandemic itself, hurdles such as small and inexperienced sponsor and clinical teams, delays in regulatory processes and research capacity in routine settings could be overcome by established research infrastructure and standardization of processes.</jats:p></jats:sec>",
"alternative-id": [
"10.3399/BJGPO.2023.0109"
],
"author": [
{
"affiliation": [],
"family": "Tare",
"given": "Dajana",
"sequence": "first"
},
{
"ORCID": "http://orcid.org/0000-0002-1238-8052",
"affiliation": [],
"authenticated-orcid": false,
"family": "Coenen",
"given": "Samuel",
"sequence": "additional"
},
{
"affiliation": [],
"family": "De Sutter",
"given": "An",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Heytens",
"given": "Stefan",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Devroey",
"given": "Dirk",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Buret",
"given": "Laetitia",
"sequence": "additional"
},
{
"ORCID": "http://orcid.org/0000-0003-1909-9613",
"affiliation": [],
"authenticated-orcid": false,
"family": "Schoenmakers",
"given": "Birgitte",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Delvaux",
"given": "Nicolas",
"sequence": "additional"
},
{
"ORCID": "http://orcid.org/0000-0002-7166-7211",
"affiliation": [],
"authenticated-orcid": false,
"family": "Verbakel",
"given": "Jan Y",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Bogaerts",
"given": "Kris",
"sequence": "additional"
},
{
"affiliation": [],
"family": "van den Bruel",
"given": "Ann",
"sequence": "additional"
}
],
"container-title": "BJGP Open",
"container-title-short": "BJGP Open",
"content-domain": {
"crossmark-restriction": false,
"domain": []
},
"created": {
"date-parts": [
[
2023,
11,
20
]
],
"date-time": "2023-11-20T13:40:11Z",
"timestamp": 1700487611000
},
"deposited": {
"date-parts": [
[
2023,
11,
20
]
],
"date-time": "2023-11-20T13:40:11Z",
"timestamp": 1700487611000
},
"indexed": {
"date-parts": [
[
2023,
11,
21
]
],
"date-time": "2023-11-21T00:14:19Z",
"timestamp": 1700525659799
},
"is-referenced-by-count": 0,
"issued": {
"date-parts": [
[
2023,
11,
20
]
]
},
"language": "en",
"link": [
{
"URL": "https://syndication.highwire.org/content/doi/10.3399/BJGPO.2023.0109",
"content-type": "unspecified",
"content-version": "vor",
"intended-application": "similarity-checking"
}
],
"member": "1987",
"original-title": [],
"page": "BJGPO.2023.0109",
"prefix": "10.3399",
"published": {
"date-parts": [
[
2023,
11,
20
]
]
},
"published-online": {
"date-parts": [
[
2023,
11,
20
]
]
},
"publisher": "Royal College of General Practitioners",
"reference-count": 0,
"references-count": 0,
"relation": {},
"resource": {
"primary": {
"URL": "http://bjgpopen.org/lookup/doi/10.3399/BJGPO.2023.0109"
}
},
"score": 1,
"short-title": [],
"source": "Crossref",
"subject": [
"Family Practice"
],
"subtitle": [],
"title": "The DAWN antivirals trial: process evaluation of a COVID-19 trial in general practice",
"type": "journal-article"
}
tarecm